A CCIPD and Cleveland Clinic study of Imaging Biomarkers for NSCLC Therapy Response presented at ASCO Annual Meeting

Wednesday, June 23, 2021 - 13:08

A study evaluating the utility of novel imaging biomarkers (radiomics) to distinguish patients with  stage 3 non-small cell lung cancer (NSCLC) may be able to predict who will benefit from treatment from those likely to progress despite therapy. 

In an interview with Physician’s Weekly, Dr. Khalid Jazieh of the Cleveland Clinic explains that the current medical procedure for stage 3 NSCLC is to treat patients with chemoradiation followed by durvalumab consolidation. This is the standard of care for everybody regardless of the potential of the patient not needing the intense treatment. For this study, CCIPD performed analyses of radiomics data to distinguish between patients with recurrence and those without.

Read more about this study on Physician’s Weekly.